Scandion Oncology reports positive topline phase IIA data from the corist part 3 trial.
Read more
Scandion Oncology
Overcoming cancer drug resistance
Navbar
About us
Executive Management
Board of Directors
Clinical Advisory Board
Research & Development
Pipeline
Clinical Development
Science
Cancer drug resistance
Technology Platform
SCO-101
News & Press
Press releases
Media
Image library
Video library
Investors
Share information
Financial calendar
Financial Reports
Annual reports
Interim reports
Presentations
Business development
Analyst Coverage
Prospectuses
Rights Issue 2022
Rights Issue 2020
Rights Issue 2019
Subscription Warrant (SCOL TO 1)
IPO 2018
Corporate governance
Events
General meetings
Contact
Career
Skip to content
BIO-Europe 2022
See the
slide deck
.
Post navigation
Investor AW
Økonomisk Ugebrev conference
